CD8A and cancer: The levels of intratumoral CD8+ TSCL and TPEX cells, but not TEX cells, are positively associated with the efficacy of cancer immunotherapies, including immune checkpoint blockade, cancer vaccination, and adoptive T cell therapy [34,35].